Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. (May 2017)

• Record Type: Journal Article
• Authors: Del Rio, M.; Mollevi, C.; Bibeau, F.; Vie, N.; Selves, J.; Emile, J.-F.; Roger, P.; Gongora, C.; Robert, J.; Tubiana-Mathieu, N.; Ychou, M.; Martineau, P.
• Is Part Of: European journal of cancer. Volume 76(2017)
• Page Start: 68
• Page End: 75
• Publication Date: 2017-05
• Subjects: Colorectal neoplasms -- FOLFIRI protocol -- Folfox protocol -- Cetuximab -- Bevacizumab -- Gene expression profiling; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2017.02.003
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Background: Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab. The aim of this study was to evaluate if recently identified molecular subtypes of colon cancer are associated with response of metastatic patients to first-line therapy. Patients and methods: We collected and analysed 143 samples of human colorectal tumours with complete clinical annotations, including the response to treatment. Gene expression profiling was used to classify patients in three to six classes using four different molecular classifications. Correlations between molecular subtypes, response to treatment, progression-free and overall survival were analysed. Results: We first demonstrated that the four previously described molecular classifications of colorectal cancer defined in non-metastatic patients also correctly classify stage IV patients. One of the classifications is strongly associated with response to FOLFIRI ( P = 0.003), but not to FOLFOX ( P = 0.911) and FOLFIRI + Bevacizumab ( P = 0.190). In particular, we identify a molecular subtype representing 28% of the patients that shows an exceptionally high response rate to FOLFIRI (87.5%). These patients have a two-fold longer overall survival (40.1 months) when treated with FOLFIRI, as first-line regimen, instead of FOLFOX (18.6 months). Conclusions: Our results demonstrate the interest of molecular classifications to develop tailored therapies for patients with metastatic colorectal cancer and a strong impact of the first-line regimen on the overall survival of some patients. This however remains to be confirmed in a large prospective clinical trial. Highlights: We analysed patient response to therapy in metastatic colorectal cancer. Patient response depends on tumour molecular subtype. First-line regimen strongly affects overall survival in some patients.